Aclidinium bromide

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist approved in the US on July 24, 2012 as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. However, it does not appear to affect the risk of death or the frequency steroids are needed. It is unclear if it differs from the similar medication tiotropium or another commonly used medication class of LAMAs.